Clinical Trials Directory

Trials / Sponsors / Ascenta Therapeutics

Ascenta Therapeutics

Industry · 10 registered clinical trials.

StatusTrialPhaseStarted
TerminatedStudy of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combinati
Acute Myelogenous Leukemia (AML)
Phase 12011-02-01
CompletedA Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men W
Hormone Refractory Prostate Cancer
Phase 22007-10-01
CompletedA Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung
Non-small Cell Lung Cancer
Phase 22007-09-01
TerminatedAn Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanc
Locally Advanced Esophageal or GE Junction Cancer
Phase 1 / Phase 22007-08-01
CompletedStudy of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
Small Cell Lung Cancer
Phase 1 / Phase 22006-11-01
CompletedSafety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular No
Follicular Lymphoma
Phase 22006-10-01
CompletedSafety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
Prostate Cancer
Phase 1 / Phase 22006-02-01
CompletedPhase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic
Chronic Lymphocytic Leukemia
Phase 22006-01-01
CompletedA Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
Hormone Refractory Prostate Cancer
Phase 1 / Phase 22005-12-01
CompletedPhase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malig
Follicular Lymphoma, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma
Phase 22005-11-01